Mometasonfuroat Glenmark (Mometasone Furoate)

Mometasone Furoate, the active ingredient in Mometasonfuroat Glenmark, is a corticosteroid presented as a topical formulation for skin use. It is employed to reduce inflammation and relieve symptoms in various dermatologic conditions affecting adults and children. It is indicated for the management of chronic inflammatory dermatoses and is formulated to ensure optimal skin penetration and patient adherence.

GNH USA supplies Mometasonfuroat Glenmark as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

Mometasone Furoate is used topically to treat inflammatory skin disorders by suppressing the underlying immune response. - Psoriasis: reduces plaque formation and scaling, improving skin appearance. - Eczema: alleviates redness, itching and swelling associated with eczema flares. - Atopic dermatitis: controls chronic inflammation and pruritus in affected areas. - Contact dermatitis: diminishes irritation caused by allergic or irritant contact. - Other inflammatory skin disorders: provides symptomatic relief in various dermatitis types.

Topical application of Mometasone Furoate may be associated with local and systemic adverse reactions.

Common Side Effects: - Burning or stinging sensation at the application site. - Mild skin irritation or erythema. - Dryness or peeling of the treated skin.

Serious or Rare Side Effects: - Secondary skin infections such as bacterial, fungal or viral. - Skin atrophy, striae or telangiectasia with prolonged use. - Systemic cortisol suppression leading to adrenal insufficiency.

Before prescribing Mometasone Furoate, clinicians should consider several safety precautions. - Duration of therapy: limit use to the shortest effective period to minimize skin thinning. - Potency: avoid use on large surface areas or under occlusion unless directed. - Age restrictions: use with caution in children under 2 years of age. - Pre‑existing infections: assess and treat any bacterial, fungal or viral skin infection before initiating therapy. - Systemic absorption: monitor for signs of hypothalamic‑pituitary‑adrenal axis suppression in extensive or prolonged treatment. - Store at ambient temperature: keep the product in the original container, protect from moisture and direct sunlight.

Mometasone Furoate can interact with other agents that affect skin integrity or systemic corticosteroid exposure.

Major Interactions (Avoid): - Systemic corticosteroids: concurrent use may increase risk of systemic adrenal suppression. - Potent immunosuppressants (e.g., tacrolimus): may exacerbate local immunosuppression and infection risk.

Moderate Interactions (Monitor Closely): - Antifungal or antibacterial topical agents: may alter absorption or increase irritation. - Skin barrier‑disrupting products (e.g., keratolytics): could enhance systemic uptake. - Phototherapy: combined use may increase skin sensitivity.